Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 5, 2009
Previous Article Next Article

Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs

Author affiliations

Abstract

Covering: 2003 to 2008

In the period 1998 to 2003, a number of reviews have appeared evaluating the potential of rapamycin and other immunophilin ligands as therapies for cancer, organ transplantation, restenosis prevention, autoimmune disorders, and neurodegenerative diseases. This review aims to evaluate advances in the field since that time, specifically detailing progress in: (i) the role of rapamycin in inhibiting its principal cellular target, the mammalian target of rapamycin (mTOR) in both of its protein complexes, (ii) understanding the role of specific genes in the mechanism of rapamycin biosynthesis, (iii) the production of novel analogs of rapamycin via precursor-directed biosynthesis, (iv) the enzymology of the pipecolate incorporating enzyme (RapL) in vitro, and (v) the pharmacology and mechanistic chemical biology of rapamycin analog mediated neuroprotection and neuroregeneration.

Graphical abstract: Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs

Back to tab navigation

Publication details

The article was received on 21 Jan 2009 and first published on 05 Mar 2009


Article type: Review Article
DOI: 10.1039/B804602F
Nat. Prod. Rep., 2009,26, 602-609

  •   Request permissions

    Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs

    E. I. Graziani, Nat. Prod. Rep., 2009, 26, 602
    DOI: 10.1039/B804602F

Search articles by author

Spotlight

Advertisements